SeedBlink Blog

By focusing on migraine prevention and other neurological challenges, Brightmind.AI offers a novel, effective approach to improving brain health through advancements in neurotechnology.

René Gilvert, CEO of Brightmind.AI, leads the company with extensive experience in the medical and neurotechnology fields. With a career-spanning leadership role at global pharmaceutical giants like Novartis and Takeda, René has been at the forefront of innovative healthcare solutions. His entrepreneurial spirit and passion for improving lives through neurotechnology are driving Brightmind.AI to deliver accessible, life-changing solutions for neurological health.

What inspired you to launch Brightmind.AI?

Brightmind.AI was founded by Tamara Gerbert with the vision to address the critical unmet needs in brain health, such as migraines and other neurological conditions, which often remain underdiagnosed or poorly treated. Tamara was driven by the desire to democratize access to effective care, bringing advanced yet simple-to-use therapies into people’s homes to make them more accessible and impactful for patients everywhere.

When I joined as a late co-founder and CEO, I was drawn to this mission by my own experience in leading medical innovation at global pharmaceutical companies. Over my career, I had seen the limitations of traditional treatments and the immense untapped potential of neuromodulation technologies. The barriers patients face—bulky hospital-bound devices, frequent clinic visits, and reliance on pharmaceuticals with side effects—highlighted the need for a different approach. I saw an opportunity to leverage my expertise to drive Brightmind.AI forward and bridge these gaps.

The team we’ve built at Brightmind.AI shares a personal and professional connection to our mission. For example, our CTO, Gregor, is a migraine sufferer who intimately understands the problem we’re solving. My background in dementia care adds another dimension of purpose, rooted in both personal and professional experiences addressing the challenges of neurological disorders.

Together, we are committed to transforming brain health by offering personalized neuromodulation technology that empowers individuals to take control of their health. Our solutions address shortcomings in access, complexity, and affordability, enabling patients to manage their conditions effectively and conveniently from home. By making advanced therapies accessible, we aim to improve lives and change the paradigm of care in brain health.

How does Brightmind.AI’s personalized neuromodulation technology work, and what makes it a breakthrough in migraine prevention?

Brightmind.AI is a platform designed to help manage and treat migraines, and in the future, other brain health conditions like dementia. We do this through cutting-edge, non-invasive brain stimulation, combined with AI-driven insights, to personalize treatments for each individual.

Our breakthrough technology is built around the idea of bringing treatments that are typically done in expensive, bulky hospital settings, right into the comfort of people’s homes. Through a compact, easy-to-use device, patients can manage their condition when and where they need to, without the need for frequent hospital visits.

What makes Brightmind.AI unique is our innovative use of AI and non-invasive brain stimulation to personalize treatment for each patient. We’ve filed patents and have others pending, ensuring that our technology stays ahead in making high-quality care accessible and convenient. Brightmind.AI is the only solution offering this combination of ease-of-use, accessibility, and cutting-edge technology, empowering patients to take control of their brain health from the comfort of their own rooms.

What challenges in brain health are you addressing?

Brightmind.AI tackles three major challenges in brain health: access, tolerability, and efficacy—critical issues that have long plagued traditional treatment approaches. Neurological conditions like migraines affect over 1 billion people worldwide, significantly impairing productivity, mental health, and overall quality of life. Yet, existing solutions often fall short.

Current treatments rely heavily on pharmaceuticals, which many patients find intolerable due to side effects or inadequate efficacy. For instance, traditional migraine treatments typically reduce the number of migraine days by 30-50%, leaving many patients underserved. In contrast, Brightmind.AI’s home-based neuromodulation solution delivers up to a 3x improvement in reducing migraine days, offering unprecedented efficacy for patients.

Access to care is another critical issue, as traditional neuromodulation devices are bulky, expensive, and confined to hospital settings, requiring multiple visits. Brightmind.AI disrupts this paradigm with a compact, easy-to-use device that empowers patients to manage their brain health conveniently from home.

Our approach doesn’t just stop at migraines. By addressing access, tolerability, and efficacy, Brightmind.AI’s personalized neuromodulation technology holds the potential to expand into other neurological conditions like Alzheimer’s disease. With our innovation, we’re solving problems no one else has been able to tackle, making advanced care accessible, effective, and life-changing for patients globally.

How does Brightmind.AI ensure its solutions are accessible and easy to use for patients in their everyday lives?

For Brightmind.AI, patient and user needs are at the core of everything we do. From the very beginning, we infused these needs into our DNA by interviewing and surveying hundreds of individuals suffering from brain health conditions. What we heard was clear: people want treatment where they want it, when they want it, and in a way that works for their lifestyle. This insight shaped our commitment to creating a solution that is easy to use, effective, and accessible to everyone, no matter their circumstances.

Our device is designed for simplicity and convenience, requiring just a few minutes per session. It’s as easy as putting it on, pressing a button, and letting the technology do the rest. There’s no need for medical supervision, no drug interactions, ensuring accessibility for all users. Paired with our intuitive mobile app, patients receive step-by-step guidance, progress tracking, and actionable insights to improve adherence and maximize results.

What truly excites us is the clinical superiority (3 times better than standard of care) matched with the speed of results. Unlike other mobile neuromodulation therapies, clinical trials have shown that users can see maximal benefits after just one week of usage, offering immediate feedback on the effectiveness of our device. This quick impact is crucial in building confidence and improving the neurological health of our users.

Affordability is another pillar of accessibility. We’ve developed innovative membership models that make at-home therapy cost-effective and sustainable. Beyond that, we are actively working with healthcare providers and insurers to integrate our device into reimbursement pathways, minimizing out-of-pocket expenses and broadening access to those who need it most.

By focusing on user needs, affordability, and rapid efficacy, Brightmind.AI is delivering on its mission to make advanced brain health solutions simple, accessible, and life-changing for patients everywhere.

What kind of feedback and impact have you seen from early adopters of Brightmind.AI’s services?

“Everyday life can be managed much better. My headaches are definitely less intense, I no longer have aura, no light sensitivity, and no nausea…”

"I can accomplish more and do more than usual, and the migraine doesn't set in. My general mood is better, and I am more resilient."

The feedback from users of our device has been nothing short of transformative. Many report significant reductions in the frequency and severity of migraines, with some experiencing noticeable benefits within just one week of use. Beyond migraine relief, users have shared how Brightmind.AI has helped them feel better overall, with fewer disruptions to their daily lives and greater confidence in managing their health.

Our technology is empowering patients to reduce their reliance on medications that often come with undesirable side effects, offering a safe, non-invasive alternative. By providing rapid relief and a user-friendly experience, Brightmind.AI is improving quality of life, enabling individuals to reclaim their productivity and enjoy their daily activities with fewer barriers.

This real-world impact reinforces the transformative potential of Brightmind.AI’s personalized neuromodulation technology in addressing neurological conditions like migraines and beyond.

What are the key milestones on Brightmind.AI’s roadmap?

Brightmind.AI’s roadmap is focused on achieving critical milestones that reflect our commitment to growth and innovation:

• Clinical validation: Completing large-scale trials to demonstrate the efficacy and safety of our neuromodulation technology, which has already shown promise in reducing migraines in early trials.
• Regulatory approvals: Securing FDA clearance and other certifications in key markets, paving the way for commercialization.
• Reimbursement pathways: Partnering with healthcare providers and insurers to ensure affordability and broad patient access.
• Third-generation device launch: Building on the success of our first two product iterations, we are scaling production for the launch of our third-generation device by 2026.
• Expansion of applications: Leveraging our personalized neuromodulation approach to tackle additional neurological conditions like depression and Alzheimer’s disease, expanding our impact on brain health care.

For investors, why is Brightmind.AI a compelling opportunity?

Brightmind.AI sits at the intersection of two booming markets: brain health and personalized healthcare. With clinically validated technology and a robust IP portfolio, we address the unmet need for effective, accessible solutions in migraine prevention while laying the groundwork for expanding into other neurological conditions.

Investors in Brightmind.AI are not just funding a product; they are supporting a proven, scalable platform designed to transform brain health. Our third-generation device combines superior efficacy and user convenience, delivering at-home care that surpasses hospital-based treatments. As Dr. Shivang Joshi, a Harvard-trained headache specialist, stated:

“The non-invasive nature of the Brightmind.AI solution, coupled with its potential for a rapid effect onset, makes it highly appealing to patients seeking an alternative to traditional medications.”

A key differentiator for Brightmind.AI is our expert team. From our experienced leadership, including commercial success by Uzair and myself, to our CTO’s MedTech expertise in transitioning prototypes to scalable production, we are positioned to deliver results. Our clinical trials are led by a neuroprofessor and TMS expert, and we benefit from an advisory board that opens access to patient networks and delivers key intelligence on competitors. This foundation strengthens every step of our journey.

By investing in Brightmind.AI, stakeholders are joining a transformative venture poised to redefine brain health care. Our personalized, at-home solutions provide superior efficacy, convenience, and affordability compared to existing treatments, making Brightmind.AI a compelling choice for investors seeking both impact and growth potential in an underserved yet high-demand market.

Explore this opportunity on SeedBlink.